611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
FDA OKs Doptelet for Liver Dz Patients Undergoing ProceduresEven a Mosquito's Spit May Help Make You SickFDA Approves Aimovig to Prevent MigrainesLower Vitamin D levels Linked to More Belly FatCan the Mediterranean Diet Protect Against Smog-Related Deaths?Many Parents Say Restaurant Fare Has Made Kids Sick: PollVarious Clinical Disturbances Precede MS DiagnosisFDA Approves First Drug Aimed at Preventing MigrainesAcute Kidney Injury in Hospital Ups Risk of Later Heart FailurePools, Hot Tubs Can Harbor Dangerous GermsAHA: 'Ideal' Heart Health Eludes More AmericansOrgans From Opioid OD Victims Are Saving Lives: StudyMore Cases in Lettuce-Linked E. Coli Outbreak, But End May Be NearFremanezumab Linked to Fewer Monthly Migraine DaysNew Rabies Test Could Save Lives, Maybe Even Minus the ShotsHealth Tip: Understanding Childhood ArthritisFDA Approves 'Biosimilar' Drug to Treat Certain Types of AnemiaColon Polyp Type May Be Key to Cancer Risk'BioSimilar' Drug Approved to Treat Certain Types of AnemiaHealth Tip: Taming a Pollen AllergyHealth Tip: Identifying Asthma Triggers'Superbug' Surfaces at Poultry Farm in ChinaSun's UV Rays a Threat to Your Eyes, TooMalnutrition Is Associated With Poor Prognosis in Heart FailureAntibiotics Tied to Higher Kidney Stone RiskMore Doubt Cast on Surgery for Spinal Compression FracturesObesity Might Raise Your Risk for A-fibAffected by the EpiPen Shortage? Here's What to DoIs Testing for Zika in U.S. Blood Supply Worth the Cost?FDA Permits Marketing of New Device for Treating GI BleedingPTSD May Raise Odds for Irregular HeartbeatNew Device Cleared for Gastrointestinal BleedingIf Kids Exposed to Pot, Tobacco Smoke, ER Visits RiseEven Mild Concussion Tied to Greater Dementia Risk LaterHealth Tip: Help Prevent E coli InfectionCBD Oil: All the Rage, But Is It Really Safe and Effective?Low Neighborhood Walkability Increases Risk of Asthma in KidsSleep-Deprived Kids at Risk of ObesityStudy IDs Pain Descriptors for Varying Stages of Low Back PainHealth Tip: Prepare for a ColonoscopyFurther Signs That Too Much Sitting Can Raise Clot RiskLightning Can Affect Deep Brain Stimulation DevicesThe Cold Truth About Migraine HeadachesHealth Tip: When To Call Your Doctor If You Have Lower Back PainSkin's 'Good' Bacteria May Be Promising Weapon Against EczemaFirst Death Reported in E. Coli Outbreak Tied to Romaine LettuceVectorborne Diseases Up More Than Two-Fold From 2004 to 2016Health Tip: Recognizing Lung DiseaseBlood Type May Play Role in Death Risk After TraumaU.S. Illnesses Tied to Ticks, Mosquitoes Are Soaring
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

New Therapy May Prevent Tough-to-Treat Migraines

HealthDay News
by -- Mary Elizabeth Dallas
Updated: Apr 17th 2018

new article illustration

TUESDAY, April 17, 2018 (HealthDay News) -- The millions of Americans who suffer from migraine may have a new source of hope -- the first of a new class of drugs aimed at warding off the headaches.

Researchers found that the injected drug, called erenumab, could prevent migraines if other treatments fail to do so.

Erenumab (brand name Aimovig) works by blocking a key brain "neurotransmitter" chemical that sends out pain signals, the research team explained.

Working with a group of people with tough-to-treat migraine, the "study found that erenumab reduced the average number of monthly migraine headaches by more than 50 percent for nearly a third of study participants," lead researcher Dr. Uwe Reuter, of The Charite University Medicine Berlin in Germany, said in a news release from the American Academy of Neurology (AAN).

The drug is currently up for approval by the U.S. Food and Drug Administration. One U.S. migraine specialist was enthused by the findings.

"We have a new class of drugs -- erenumab likely to be the first to be on the market -- that are showing great promise in preventing migraine attacks," said Dr. Randall Berliner. He's an adjunct neurologist at Lenox Hill Hospital in New York City and wasn't involved in the new trial.

As Berliner explained, it's been a long, tough road to find medicines that provide reliable relief to migraine sufferers.

Twenty years ago, a group of drugs called triptans were introduced, and have since become the standard of care, he said. But they don't work for everyone.

Erenumab, and meds like it, target "calcitonin gene-related peptide" (CGRP). Erenumab acts to stop this neurotransmitting chemical from binding to a nerve and sending out migraine pain signals.

"Our bodies typically produce antibodies to fight off infections, cancers and other foreign agents that the immune system deems harmful. But physicians and scientists have learned to develop antibodies that can target agents that cause disease: tumors, abnormal immune cells, and now CGRP," Berliner explained.

"In so doing, erenumab very safely blocks a good deal of the migraines from occurring in the first place," Berliner said.

The new study was funded by drug maker Novartis. In their research, Reuter's team tested erenumab on 246 people with the treatment-resistant migraine.

Of these participants, 39 percent had already failed to respond to two available migraine medications, 38 percent were treated with three other medications and 23 percent had tried four different medications to help control their migraines.

On average, these migraine sufferers experienced nine migraine headaches each month and took an acute migraine drug to stop an attack five times each month.

During the study, each person received injections of either 140 milligrams of erenumab or a "dummy" placebo once per month for three months.

After three months, those treated with erenumab were almost three times as likely to have fewer days with migraine pain, compared to people who'd only gotten the placebo. Days with migraine headaches were reduced by at least 50 percent compared to those who were given the placebo. In addition to fewer days with headaches, these patients also took acute migraine drugs less often.

Of all the participants, 30 percent treated with erenumab said their migraine frequency drop by half. The same was true for only 14 percent in the placebo group. The drug was also not associated with significant side effects.

All of this "can greatly improve a person's quality of life," Reuter said. "Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief."

What's the next step? According to Reuter, "more research is now needed to understand who is most likely to benefit from this new treatment."

The researchers added that larger studies are also needed to evaluate the long-term safety and effectiveness of the medication.

Dr. Noah Rosen directs the Headache Center at Northwell Health's Neuroscience Institute in Great Neck, N.Y. He agreed that "too many people have suffered because a lack of good migraine-specific prevention and from the side effects of many of the currently available options. If we are able to figure out which migraine sufferers are most likely to benefit from this treatment, it will also let us provide care more effectively."

The study findings haven't been published yet, but are expected to be presented next Tuesday at the AAN's annual meeting in Los Angeles. Experts note that findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

More information

The American Academy of Family Physicians has more on migraine.